Non-small cell lung cancer
Clinical research includes advanced non-small cell lung cancer and locally advanced unresectable stage III NSCLC, with interest in combining radiotherapy with systemic and local treatment approaches.
- Radioenhancing cancer therapy
- Chemoradiation
- Immune checkpoint inhibition
- Durvalumab
The portfolio reflects a focus on treatment strategies for lung tumors that are difficult to control with standard local therapy alone.
Head and neck cancer
Research activity also covers locally advanced head and neck squamous cell carcinoma, with attention to tumor-directed approaches used alongside radiotherapy.
- Head and neck squamous cell carcinoma
- Cetuximab
- Local tumor activation
- Radiation-based treatment
This area centers on cancers where local disease control and preservation of function are major therapeutic priorities.
Advanced solid tumors
The sponsor funds studies in advanced solid tumors, including approaches designed for direct tumor targeting and combination use with immunotherapy or radiotherapy.
- Advanced solid tumors
- Intratumoral therapy
- Tumor-targeting virus
- Combination oncology treatment
These studies extend beyond a single tumor type and address broader needs in difficult-to-treat malignant disease.
Oncology immunotherapy and radiotherapy combinations
A significant research theme is the pairing of immune-based cancer therapy with radiotherapy in solid tumors, including evaluation of agents that modulate the tumor microenvironment.
- A2a receptor antagonist
- Cetrelimab
- Tumor microenvironment
- Combination immuno-oncology
Work in this domain spans both local and systemic treatment concepts for cancer control.
